A recent FDA webinar for manufacturers of neurological devices that could be cleared for market via the de novo pathway centered on the importance of pre-submission meetings to ensure a smooth regulatory process.
“If you think it's too early to contact us, that is exactly the right time to contact us,” said Carlos Peña, director of the division of neurological and physical medicine devices
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?